Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract 5079: Comparative studies of chemotherapy and immuno-oncology combinations in multiple mouse syngeneic tumor models

Eunsil Park, Marlene Hinton, Mingmei Cai, Malgorzata A. Gil, Gustave Hebert, Long Cui, Doug Linn, Brian J. Long, Evan R. Barry

Cancer Res (2024) 84 (6_Supplement): 5079.

https://doi.org/10.1158/1538-7445.AM2024-5079

Published: 22 March 2024

View article titled, Abstract 5079: Comparative studies of chemotherapy and immuno-oncology combinations in multiple mouse syngeneic tumor models

Journal Articles

Abstract 4615: Measurement of systemic inflammatory responses in mouse syngeneic tumor models

Nicolas Solban, Douglas Linn, Cai Li, Razvan Cristescu, Brian J. Long

Cancer Res (2019) 79 (13_Supplement): 4615.

https://doi.org/10.1158/1538-7445.AM2019-4615

Published: 01 July 2019

View article titled, Abstract 4615: Measurement of systemic inflammatory responses in mouse syngeneic tumor models

Journal Articles

Abstract 4721: Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors

Cancer Res (2018) 78 (13_Supplement): 4721.

https://doi.org/10.1158/1538-7445.AM2018-4721

Published: 01 July 2018

View article titled, Abstract 4721: Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors

Journal Articles

Abstract 1657: Evaluating anti-tumor activity of the human anti-PD-1 antibody pembrolizumab using humanized mouse models

Douglas E. Linn, Razvan Cristescu, Kallol Ray, Shuli Zhang, Sripriya Dhandapani, Sarav Kaliyaperumal, Jennifer H. Yearley, Brian J. Long

Cancer Res (2017) 77 (13_Supplement): 1657.

https://doi.org/10.1158/1538-7445.AM2017-1657

Published: 01 July 2017

View article titled, Abstract 1657: Evaluating anti-tumor activity of the human anti-PD-1 antibody pembrolizumab using humanized mouse models

Journal Articles

Abstract 269: Evaluation of the antitumor activity of anti-PD-1 immunotherapy as a single agent and in combination with approved agents in preclinical tumor models

Elaine M. Pinheiro, Ruban Mangadu, Uyen T. Phan, Mingmei Cai, Yanhong Ma, Heather A. Hirsch, Terrill K. McClanahan, Raymond J. Moniz, Ali-Samer Al-Assaad, Samik Basu, Yaolin Wang, Venkataraman Sriram, Joseph H. Phillips, Brian J. Long

Cancer Res (2015) 75 (15_Supplement): 269.

https://doi.org/10.1158/1538-7445.AM2015-269

Published: 01 August 2015

View article titled, Abstract 269: Evaluation of the antitumor activity of anti-PD-1 immunotherapy as a single agent and in combination with approved agents in preclinical tumor models

Journal Articles

Abstract 599: TMPRSS2-ERG gene fusion sensitizes VCaP human prostate tumors to the fully human anti-IGF-IR monoclonal antibody SCH 717454

Brian J. Long, Patrick Groothuis, Stacey Taylor, Gongjie Liu, Gaby Terracina, Ming Liu, Maureen Laverty, Eric L. Gustafson, Yaolin Wang, Yan Wang, Cynthia Seidel-Dugan, Daniel Hicklin

Cancer Res (2011) 71 (8_Supplement): 599.

https://doi.org/10.1158/1538-7445.AM2011-599

Published: 15 April 2011

View article titled, Abstract 599: TMPRSS2-ERG gene fusion sensitizes VCaP human prostate tumors to the fully human anti-IGF-IR monoclonal antibody SCH 717454

Journal Articles

Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole

Gauri J. Sabnis, Danijela Jelovac, Brian J. Long, Adam Schayowitz, Aashvini Belosay, Angela M. H. Brodie

Cancer Res (2006) 66 (8_Supplement): 547.

Published: 15 April 2006

View article titled, Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole

Journal Articles

Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole

Danijela Jelovac, Gauri Sabnis, Brian J. Long, Luciana Macedo, Olga G. Goloubeva, Angela M.H. Brodie

Cancer Res (2005) 65 (12): 5380–5389.

https://doi.org/10.1158/0008-5472.CAN-04-4502

Published: 15 June 2005

View article titled, Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole

Journal Articles

Effects of the farnesyl transferase inhibitor lonafarnib on function and signaling of the small GTPase Rheb

Andrea D. Basso, Asra Mirza, Gongjie Liu, Brian J. Long, W. Robert Bishop, Paul Kirschmeier

Cancer Res (2005) 65 (9_Supplement): 1403.

Published: 01 May 2005

View article titled, Effects of the farnesyl transferase inhibitor lonafarnib on function and signaling of the small GTPase Rheb

Journal Articles

Lonafarnib, an orally active farnesyl transferase inhibitor (FTI), enhances the growth inhibitory effects of taxanes on ovarian cancers: correlation of efficacy with pharmacodymanic markers

Brian J. Long, Gongjie Liu, Cindy H. Marrinan, Lissette Delgado, Andrea Basso, Ming Liu, Paul Kirschmeier, W. Robert Bishop

Cancer Res (2005) 65 (9_Supplement): 1404.

Published: 01 May 2005

View article titled, Lonafarnib, an orally active farnesyl transferase inhibitor (FTI), enhances the growth inhibitory effects of taxanes on ovarian cancers: correlation of efficacy with pharmacodymanic markers

Journal Articles

Strategies to oppose loss of sensitivity to hormone therapy in breast cancer cells

Danijela Jelovac, Gauri Sabnis, Brian J. Long, Luciana Macedo, Angela Brodie

Cancer Res (2005) 65 (9_Supplement): 1032.

Published: 01 May 2005

View article titled, Strategies to oppose loss of sensitivity to hormone therapy in breast cancer cells

Journal Articles

Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts

Brian J. Long, Gongjie Liu, Cindy H. Marrinan, Eugene Maxwell, Stuart Black, Ferdous Gheyas, Amin Nomeir, Ming Liu, Paul Kirschmeier, W. Robert Bishop

Cancer Res (2004) 64 (7_Supplement): 892.

Published: 01 April 2004

View article titled, Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts

Journal Articles

Signaling Pathways of Apoptosis Activated by Aromatase Inhibitors and Antiestrogens

Apinya Thiantanawat, Brian J. Long, Angela M. Brodie

Cancer Res (2003) 63 (22): 8037–8050.

Published: 21 November 2003

View article titled, Signaling Pathways of Apoptosis Activated by Aromatase Inhibitors and Antiestrogens

Journal Articles

Antiandrogenic Effects of Novel Androgen Synthesis Inhibitors on Hormone-dependent Prostate Cancer

Brian J. Long, Dmitry N. Grigoryev, Ivo P. Nnane, Yang Liu, Yang-Zhi Ling, Angela M. Brodie

Cancer Res (2000) 60 (23): 6630–6640.

Published: 01 December 2000

View article titled, Antiandrogenic Effects of Novel Androgen Synthesis Inhibitors on Hormone-dependent Prostate Cancer

Journal Articles

Human Breast Cancer Cells Contain an Error-prone DNA Replication Apparatus

Jennifer W. Sekowski, Linda H. Malkas, Lauren Schnaper, Pamela E. Bechtel, Brian J. Long, Robert J. Hickey

Cancer Res (1998) 58 (15): 3259–3263.

Published: 01 August 1998

View article titled, Human Breast Cancer Cells Contain an Error-prone DNA Replication Apparatus

Journal Articles

A Unique Form of Proliferating Cell Nuclear Antigen Is Present in Malignant Breast Cells

Pamela E. Bechtel, Robert J. Hickey, Lauren Schnaper, Jennifer W. Sekowski, Brian J. Long, Robert Freund, Ni Liu, Carla Rodriguez-Valenzuela, Linda H. Malkas

Cancer Res (1998) 58 (15): 3264–3269.

Published: 01 August 1998

View article titled, A Unique Form of Proliferating Cell Nuclear Antigen Is Present in Malignant Breast Cells

NARROW

Abstract 5079: Comparative studies of chemotherapy and immuno-oncology combinations in multiple mouse syngeneic tumor models

Abstract 4615: Measurement of systemic inflammatory responses in mouse syngeneic tumor models

Abstract 4721: Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors

Abstract 1657: Evaluating anti-tumor activity of the human anti-PD-1 antibody pembrolizumab using humanized mouse models

Abstract 269: Evaluation of the antitumor activity of anti-PD-1 immunotherapy as a single agent and in combination with approved agents in preclinical tumor models

Abstract 599: TMPRSS2-ERG gene fusion sensitizes VCaP human prostate tumors to the fully human anti-IGF-IR monoclonal antibody SCH 717454

Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole

Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole

Effects of the farnesyl transferase inhibitor lonafarnib on function and signaling of the small GTPase Rheb

Lonafarnib, an orally active farnesyl transferase inhibitor (FTI), enhances the growth inhibitory effects of taxanes on ovarian cancers: correlation of efficacy with pharmacodymanic markers

Strategies to oppose loss of sensitivity to hormone therapy in breast cancer cells

Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts

Signaling Pathways of Apoptosis Activated by Aromatase Inhibitors and Antiestrogens

Antiandrogenic Effects of Novel Androgen Synthesis Inhibitors on Hormone-dependent Prostate Cancer

Human Breast Cancer Cells Contain an Error-prone DNA Replication Apparatus

A Unique Form of Proliferating Cell Nuclear Antigen Is Present in Malignant Breast Cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only